1. Home /
  2. Biotechnology

Biotechnology

Cambrex Soars on Buyout Deal With Private-Equity Firm Permira

Cambrex Soars on Buyout Deal With Private-Equity Firm Permira

Shares of life-sciences company Cambrex surge after the company strikes a deal to be acquired by pharmaceutical-focused private-equity firm Permira funds for $2.4 billion, including debt.

Allakos Stock Doubles on Positive Stomach Disease Drug Study Data

Allakos Stock Doubles on Positive Stomach Disease Drug Study Data

Analyst at William Blair says Allakos is a leader in research for a treatment for a rare stomach disease.

GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails

GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails

The company announces that rivipansel, which was developed in partnership with Pfizer, didn't meet primary or secondary endpoints.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Amgen Changes the Narrative With Cancer Drug Breakthrough

Amgen Changes the Narrative With Cancer Drug Breakthrough

Amgen built on the momentum at a recent conference on its Q2 earnings call as management highlighted recent positive developments for its KRAS inhibitor drug.

Swinging for the Small-Cap Biotech Fences Requires Accepting Strikeouts

Swinging for the Small-Cap Biotech Fences Requires Accepting Strikeouts

Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.

Simulations Plus Can't Go Up Forever, so It's Time to Book the Profits

Simulations Plus Can't Go Up Forever, so It's Time to Book the Profits

Parabolic moves can be alluring, but if you are long on SLP, consider how far it can fall from here.

Short-Seller Left Goes Long on Invitae With $100 Target

Short-Seller Left Goes Long on Invitae With $100 Target

Citron analyst sees 'indestructible moat' around genetic-testing company's business.

Biggest Earnings Wednesday: GE, AMC Networks, Spotify and More

Biggest Earnings Wednesday: GE, AMC Networks, Spotify and More

Another day, another busy earnings day! What to watch on Wednesday, July 31, 2019.

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.